Warning letter
Staska Pharmaceuticals, Inc.: warning letter of May 5, 2025
FDA warning letter 699291 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 699291 |
|---|---|
| Company | Staska Pharmaceuticals, Inc. |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | May 5, 2025 |
| Posted date | Jul 1, 2025 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 210.1(b), 200.10(b), 201.115, 211.25(a), 211.42(c)(10)(iv), 211.67(a), 211.100(a), 211.113(b), 211.192 |
| Inspection city | Bennet |
| Inspection ZIP | 68317 |
| Inspection start date | Sep 3, 2024 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: